These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 2017610

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Survey of Bacteroides fragilis group susceptibility patterns in Canada.
    Bourgault AM, Lamothe F, Hoban DJ, Dalton MT, Kibsey PC, Harding G, Smith JA, Low DE, Gilbert H.
    Antimicrob Agents Chemother; 1992 Feb; 36(2):343-7. PubMed ID: 1605600
    [Abstract] [Full Text] [Related]

  • 6. Resistance trends of Bacteroides fragilis group over an 8-year period, 1997-2004, in Korea.
    Roh KH, Kim S, Kim CK, Yum JH, Kim MS, Yong D, Lee K, Kim JM, Chong Y.
    Korean J Lab Med; 2009 Aug; 29(4):293-8. PubMed ID: 19726890
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994.
    Snydman DR, McDermott L, Cuchural GJ, Hecht DW, Iannini PB, Harrell LJ, Jenkins SG, O'Keefe JP, Pierson CL, Rihs JD, Yu VL, Finegold SM, Gorbach SL.
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S54-65. PubMed ID: 8953108
    [Abstract] [Full Text] [Related]

  • 9. Prevalence and antimicrobial susceptibility of enterotoxigenic extra-intestinal Bacteroides fragilis among 13-year collection of isolates in Kuwait.
    Jamal W, Khodakhast FB, AlAzmi A, Sόki J, AlHashem G, Rotimi VO.
    BMC Microbiol; 2020 Jan 15; 20(1):14. PubMed ID: 31941446
    [Abstract] [Full Text] [Related]

  • 10. Epidemiology and antimicrobial resistance of B. fragilis group organisms isolated from clinical specimen and human intestinal microbiota.
    de Carvalho CB, Moreira JL, Ferreira MC.
    Rev Inst Med Trop Sao Paulo; 1996 Jan 15; 38(5):329-35. PubMed ID: 9293074
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Evolution of antimicrobial susceptibility in isolates of the Bacteroides fragilis group in Spain.
    García-Rodríguez JE, García-Sánchez JE.
    Rev Infect Dis; 1990 Jan 15; 12 Suppl 2():S142-51. PubMed ID: 2305180
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. In-vitro activity of amoxycillin and ticarcillin in combination with clavulanic acid compared with that of new beta-lactam agents against species of the Bacteroides fragilis group.
    Bourgault AM, Lamothe F.
    J Antimicrob Chemother; 1986 May 15; 17(5):593-603. PubMed ID: 3636324
    [Abstract] [Full Text] [Related]

  • 17. In vitro susceptibility of clinical isolates of Bacteroides fragilis and Bacteroides thetaiotaomicron in Japan.
    Watanabe K, Ueno K, Kato N, Muto Y, Bandoh K, Tanaka Y, Jotwani R, Goto M, Shimada K, Shimizu K.
    Eur J Clin Microbiol Infect Dis; 1992 Nov 15; 11(11):1069-73. PubMed ID: 1295761
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effectiveness of cefotaxime alone and in combination with desacetylcefotaxime against Bacteroides fragilis.
    Wasilauskas BL.
    Diagn Microbiol Infect Dis; 1989 Nov 15; 12(1):39-43. PubMed ID: 2714071
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.